Dott. Ugo De Giorgi
Responsabile del Gruppo di Patologia Uro-Ginecologico presso Istituto
Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) – IRCCS, Meldola (FC)
CREDITI FORMATIVI ECM
Dueci Promotion S.r.l., Provider ECM n.1463, ha accreditato l’incontro ottenendo
n. 6 crediti per le seguenti figure professionali:
› Medico Chirurgo specializzato in:
•Oncologia
•Radioterapia
•Urologia
• Anatomia patologica
• Laboratorio di genetica medica
• Medicina nucleare
› Farmacista specializzato in:
• Farmacia ospedaliera
• Farmacia Territoriale
› Biologo
› Infermiere
Biomarkers in the
treatment selection
in prostate cancer
› Psicologo specializzato in:
•Psicoterapia
•Psicologia
MODALITÀ DI ISCRIZIONE
L’iscrizione è gratuita e si effettua esclusivamente on line:
www.duecipromotion.com > Congressi Medici > Calendario Congressi
> Registrazione on line
SEGRETERIA ORGANIZZATIVA E PROVIDER 1463
Dueci Promotion
Via C. Farini 28 - 40124 Bologna
Tel 051.4841310 fax 051.247165
[email protected]
www.duecipromotion.com
Meldola - Forli
Istituto Scientifico Romagnolo per lo Studio
e la Cura dei Tumori (IRST) – IRCCS
CON IL CONTRIBUTO DI:
Venerdì
Informazioni
RESPONSABILE SCIENTIFICO
18 Marzo
2016
Programma
08.30 Attendees registration
09.00 Introduction and presentation
D. Amadori, IRST IRCCS, Scientific Director
U.De Giorgi, IRST IRCCS, Head GU Unit
I SESSION
Biomarkers in prostate cancer – hormonal therapies
Chairmen: G. Attard, London - F. Demichelis, Trento
11.50 Timing of Radium-223 therapy
Speaker: V. Conteduca, Meldola
12.10 Role of PMSA in radiometabolic–based strategy
Speaker: G. Paganelli, Meldola
12.30 Discussion on presented topics
12.50 Testicular germ cell tumour
Lecture:
09.30 Molecular classification for precision medicine in prostate
cancer management
Speaker: G. Attard, London
An overview of genetics and possible biomarkers for disease progression
and relapse
Speaker: A. Reid, London
09.50 Different approaches for the whole identification of genomic aberrations
Speaker: D. Wetterskog, London
13.15 Lunch
10.10 Resistance to novel hormonal drugs and biomarkers
of treatment response
Speaker: F. Demichelis, Trento
10.30 Discussion on presented topics
10.45 Coffee break
II SESSION
Biomarkers in prostate cancer – chemotherapeutic and
radiometabolic approaches
III SESSION
ProTeam - Meeting with prostate cancer patients
and caregivers
14.30 Round table with prostate cancer patients and caregivers
Chairman: U. De Giorgi, Meldola
ProTeam presentation, G. Giusti, Rozzano
Nutrition and prostate cancer, L. Bedei, Forlì
Bone health, T. Ibrahim, Meldola
Andrology issues, R. Gunelli, Forlì
Psychology, T. Bertelli, Meldola
Chairmen: U. De Giorgi, Meldola - V. Casadio, Meldola
17.30 Conclusion
11.10 AR status and docetaxel therapy
Speaker: A. Jayaram, London
18:00 CME questionnarie and closing remarks
11.30 Novel predictive factors for cabazitaxel therapy
Speaker: S. Salvi, Meldola